PRRT2 and lung carcinoma: Combination therapies, especially those involving MET inhibition, have been increasingly studied as a treatment strategy in lung cancer.[21–24] Given the current knowledge of roles of MET, a growth-factor receptor, PKCß, an intracellular target in lung cancer and the efficacy of their inhibition as independent targets, we have investigated whether their dual inhibition leads to increased cytotoxicity against NSCLC in vitro.